8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Dexcom CEO Jake Leach to present at J.P.
Filed with the SEC on · Summarized by InvestorsBot
Dexcom CEO Jake Leach to present at J.P. Morgan Healthcare Conf on Jan 12, 2026 at 10:30 AM ET — will report preliminary, unaudited Q4 2025 & FY2025 results and provide initial FY2026 revenue/margin outlook. $DXCM 📈🕙 #JPM2026 #MedTech #Earnings
Dexcom notes Q4/FY2025 figures are preliminary, unaudited and subject to finalization in the FY2025 Form 10‑K; FY2026 guidance covers total revenue and Non‑GAAP gross & operating margin expectations. $DXCM ⚠️ #Investing #MedTech
Dexcom issued a Jan 12 press release with the preliminary results (Exhibit 99.1) and a Jan 7 business update (Exhibit 99.2). Information is furnished—not “filed” under Exchange Act Section 18. $DXCM 📄 #DXCM #InvestorAlert